Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-22
2011-03-22
Ton, Thaian N (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000
Reexamination Certificate
active
07910567
ABSTRACT:
The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterized by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.
REFERENCES:
patent: 5827702 (1998-10-01), Cuthbertson
patent: 6413931 (2002-07-01), Hook et al.
patent: 2002/0115589 (2002-08-01), Nixon et al.
patent: 2003/0148351 (2003-08-01), Henry et al.
patent: 2007/0021334 (2007-01-01), Bishop
patent: 2008/0096793 (2008-04-01), Bishop et al.
patent: 4445630 (1996-06-01), None
patent: 97/15330 (1997-05-01), None
patent: 98/13071 (1998-04-01), None
patent: 98/24466 (1998-06-01), None
patent: 01/19386 (2001-03-01), None
patent: 2004/105784 (2004-12-01), None
patent: 2006/043031 (2006-04-01), None
Tomasoni and Benigni (Current Gene Therapy 4: 115-122, 2004).
Gautam et al. (Am J Respir Med 1(1):2002:35-46).
Yang. Radiology 228:36-49, 2003.
Le Goff et al. IOVS, (Apr. 2004), 45:supplement 1, abstract pp. U742.
Canfield, A.E. et al., “Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells,” J. Cell Sci. (1995) 108:797-809.
Friedman, J.S. et al., “Protein localization in the human eye and genetic screen of opticin,” Human Mol. Genet. (2002) 11(11):1333-1342.
Le Goff et al., “Characterization of opticin and evidence of stable dimerisation in solution,” J. Biol. Chem. (2003) 278:45280-45287.
Pellegrini, B. et al., “Cloning and characterization of opticin cDNA: evaluation as a candidate for canine oculo-skeletal dysplasia,” Gene (2002) 282:121-131.
Slevin, M. et al., “Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses,” J. Biol. Chem. (2002) 277:41046-41059.
Stander, M. et al., “Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth,” Cell Tiss. Res. (1999) 296(2):221-227.
Tasheva, E.S., “Analysis of the promoter region of human mimecan gene,” Biochimica et Biophysica Acta (2002) 1575(1-3):123-129.
Tralhao, J. G. et al., “In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer,” The FASEB Journal (2003) 17(3):464-466.
Vuillermoz, B. et al., “The small leucine-rich proteoglycan lumican inhibits melanoma progression,” Exp. Cell Res. (2004) 296(2):294-306.
International Search Report for Application No. PCT/GB2004/002269 dated Nov. 18, 2004 (4 pages).
Written Opinion for Application No. PCT/GB2004/002269 dated Nov. 18, 2004 (8 pages).
International Preliminary Report on Patentability for Application No. PCT/GB2004/002269 dated Oct. 20, 2005 (11 pages).
International Search Report for Application No. PCT/GB2005/003940 dated Apr. 3, 2006 (3 pages).
Written Opinion for Application No. PCT/GB2005/003940 dated Apr. 3, 2006 (6 pages).
United States Patent Office Action for U.S. Appl. No. 10/558,606 dated Apr. 20, 2007 (6 pages).
United States Patent Office Action for U.S. Appl. No. 10/558,606 dated Nov. 20, 2007 (6 pages).
Michael & Best & Friedrich LLP
Noble Marcia S
The University of Manchester
Ton Thaian N
LandOfFree
Opticin nucleic acid administration reduces blood vessel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opticin nucleic acid administration reduces blood vessel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opticin nucleic acid administration reduces blood vessel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696431